Markets

Integra Reports Organic Sales Drop in Preliminary Q2 Results

Integra LifeSciences Holdings Corporation IART recently announced the preliminary revenue results for second-quarter 2020. The company is scheduled to release detailed financial results for the period on Aug 10.

Integra projects second-quarter 2020 revenues in the band of $254-$256 million. This represents an organic revenue decline of 32% and 34% on a reported basis. The Zacks Consensus Estimate for the same is currently pinned at $255 million.

Management noted that there was a sequential improvement in monthly sales performance throughout the quarter due to the reopening of non-emergent surgical procedures and the easing of shelter-in-place restrictions. However, the average daily sales for the company in June were down 15% year over year

2020 Guidance

Integra LifeSciences, although upbeat about its improvement in monthly sales trends during the second quarter, is wary about the uncertainties related to the pandemic’s impacts. Hence, it is currently unable to estimate the revenue impact due to COVID-19 beyond the first half of 2020.
 
The company will, however, provide an update on Aug 10.

As of now, the Zacks Consensus Estimate for 2020 adjusted earnings per share is pegged at $1.77, while the same for revenues is $1.31 billion.

Price Performance

Shares of the company have lost 11.5% in the past year against the industry’s 10.4% growth and the S&P 500's 5.8% rise.



 

Zacks Rank & Other Key Picks

Currently, Integra carries a Zacks Rank #2 (Buy).

A few other top-ranked stocks from the broader medical space include Quest Diagnostics Incorporated DGX, Laboratory Corporation of America Holdings LH or LabCorp and QIAGEN N.V. QGEN.

Quest Diagnostics’ long-term earnings growth rate is projected at 7.6%. It currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

LabCorp’s long-term earnings growth rate is estimated at 6.1%. The company presently sports a Zacks Rank #1.

QIAGEN’s long-term earnings growth rate is estimated at 18.3%. It currently flaunts a Zacks Rank #1.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.

See the pot trades we're targeting>>


Click to get this free report

Quest Diagnostics Incorporated (DGX): Free Stock Analysis Report

Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report

QIAGEN N.V. (QGEN): Free Stock Analysis Report

Laboratory Corporation of America Holdings (LH): Free Stock Analysis Report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More